Hans J. Woerle: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

51

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

Kadowaki, Takashi, Haneda, Masakazu, Inagaki, Nobuya, Terauchi, Yasuo, Taniguchi, Atsushi, Koiwai, Kazuki, Rattunde, Henning, Woerle, Hans J., Broedl, Uli C.

Journal:

Advances in Therapy

Year:

2014

Language:

english

File:

PDF, 1.47 MB

english, 2014

52

Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)—A Pooled Comprehensive Post-Hoc Analysis

Zinman, Bernard, Ahrén, Bo, Neubacher, Dietmar, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans J.

Journal:

Canadian Journal of Diabetes

Year:

2014

Language:

english

File:

PDF, 47 KB

english, 2014

53

Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

Merker, Ludwig, Lund, Soeren S., Hantel, Stefan, Salsali, Afshin, Kim, Gabriel, Broedl, Uli, Woerle, Hans J., Hach, Thomas

Journal:

Canadian Journal of Diabetes

Year:

2014

Language:

english

File:

PDF, 107 KB

english, 2014

54

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

Thrasher, James, Daniels, Kristen, Patel, Sanjay, Whetteckey, Jacqueline, Woerle, Hans-Juergen

Journal:

Endocrine Practice

Year:

2014

Language:

english

File:

PDF, 960 KB

english, 2014

55

Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)

Ridderstråle, Martin, Andersen, Knut Robert, Zeller, Cordula, Kim, Gabriel, Woerle, Hans J., Broedl, Uli

Journal:

Canadian Journal of Diabetes

Year:

2014

Language:

english

File:

PDF, 51 KB

english, 2014

56

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

Nicolaus, Mathias, Brödl, Julia, Linke, Rainer, Woerle, Hans-Juergen, Göke, Burkhard, Schirra, Jörg

Journal:

Journal of Clinical Endocrinology & Metabolism

Year:

2011

Language:

english

File:

PDF, 245 KB

english, 2011

57

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus

Sarashina, Akiko, Ueki, Kohjiro, Sasaki, Tomohiro, Tanaka, Yuko, Koiwai, Kazuki, Sakamoto, Wataru, Woerle, Hans J., Salsali, Afshin, Broedl, Uli C., Macha, Sreeraj

Journal:

Clinical Therapeutics

Year:

2014

Language:

english

File:

PDF, 258 KB

english, 2014

58

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

Kanada, Shigeto, Koiwai, Kazuki, Taniguchi, Atsushi, Sarashina, Akiko, Seman, Leo, Woerle, Hans J

Journal:

Journal of Diabetes Investigation

Year:

2013

Language:

english

File:

PDF, 194 KB

english, 2013

59

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial: Figure 1

Perkins, Bruce A., Cherney, David Z.I., Partridge, Helen, Soleymanlou, Nima, Tschirhart, Holly, Zinman, Bernard, Fagan, Nora M., Kaspers, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., Johansen, Odd-Er

Journal:

Year:

2014

Language:

english

File:

PDF, 785 KB

english, 2014

60

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Seman, Leo, Macha, Sreeraj, Nehmiz, Gerhard, Simons, Gudrun, Ren, Bailuo, Pinnetti, Sabine, Woerle, Hans J., Dugi, Klaus

Journal:

Clinical Pharmacology in Drug Development

Year:

2013

Language:

english

File:

PDF, 451 KB

english, 2013

61

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Cherney, David Z I, Perkins, Bruce A, Soleymanlou, Nima, Xiao, Fengxia, Zimpelmann, Joseph, Woerle, Hans-Juergen, E Johansen, Odd, Broedl, Uli C, von Eynatten, Maximilian, Burns, Kevin D

Journal:

Kidney International

Year:

2014

Language:

english

File:

PDF, 215 KB

english, 2014

62

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

Laakso, Markku, Rosenstock, Julio, Groop, Per-Henrik, Barnett, Anthony H., Gallwitz, Baptist, Hehnke, Uwe, Tamminen, Ilkka, Patel, Sanjay, von Eynatten, Maximilian, Woerle, Hans-Juergen

Journal:

Year:

2015

Language:

english

File:

PDF, 825 KB

english, 2015

63

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

DeFronzo, Ralph A., Lewin, Andrew, Patel, Sanjay, Liu, Dacheng, Kaste, Renee, Woerle, Hans J., Broedl, Uli C.

Journal:

Year:

2015

Language:

english

File:

PDF, 1.14 MB

english, 2015

64

C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study: Table 1

Johansen, Odd Erik, Boehm, Bernhard O., Grill, Valdemar, Torjesen, Peter A., Bhattacharya, Sudipta, Patel, Sanjay, Wetzel, Kristiane, Woerle, Hans-Juergen

Journal:

Year:

2014

Language:

english

File:

PDF, 498 KB

english, 2014

65

Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis

Zeng, Zhengpei, Choi, Dong Seop, Mohan, Viswanathan, Emser, Angela, Siddiqui, Kamran, Gong, Yan, Patel, Sanjay, Woerle, Hans-Juergen

Journal:

Current Medical Research and Opinion

Year:

2015

Language:

english

File:

PDF, 452 KB

english, 2015

66

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials

Lajara, Rosemarie, Aguilar, Richard, Hehnke, Uwe, Woerle, Hans-Juergen, von Eynatten, Maximilian

Journal:

Clinical Therapeutics

Year:

2014

Language:

english

File:

PDF, 265 KB

english, 2014

67

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

Riggs, Matthew M., Seman, Leo J., Staab, Alexander, MacGregor, Thomas R., Gillespie, William, Gastonguay, Marc R., Woerle, Hans J., Macha, Sreeraj

Journal:

British Journal of Clinical Pharmacology

Year:

2014

Language:

english

File:

PDF, 1.60 MB

english, 2014

68

Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes

Friedrich, Christian, Emser, Angela, Woerle, Hans-Juergen, Graefe-Mody, Ulrike

Journal:

American Journal of Therapeutics

Year:

2013

Language:

english

File:

PDF, 113 KB

english, 2013

69

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Škrtić, Marko, Yang, Gary K., Perkins, Bruce A., Soleymanlou, Nima, Lytvyn, Yuliya, von Eynatten, Maximilian, Woerle, Hans J., Johansen, Odd Erik, Broedl, Uli C., Hach, Thomas, Silverman, Melvin, Cher

Journal:

Year:

2014

Language:

english

File:

PDF, 180 KB

english, 2014

70

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

Kadowaki, Takashi, Haneda, Masakazu, Inagaki, Nobuya, Terauchi, Yasuo, Taniguchi, Atsushi, Koiwai, Kazuki, Rattunde, Henning, Woerle, Hans J., Broedl, Uli C.

Journal:

Advances in Therapy

Year:

2015

Language:

english

File:

PDF, 1.35 MB

english, 2015

71

2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)

Johansen, Odd Erik, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans J.

Journal:

Nederlands Tijdschrift voor Diabetologie

Year:

2013

File:

PDF, 102 KB

2013

72

Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study

Heise, Tim, Mattheus, Michaela, Woerle, Hans J., Broedl, Uli C., Macha, Sreeraj

Journal:

Clinical Therapeutics

Year:

2015

Language:

english

File:

PDF, 267 KB

english, 2015

73

Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus

Sheu, Wayne H.-H., Park, Sung Woo, Gong, Yan, Pinnetti, Sabine, Bhattacharya, Sudipta, Patel, Sanjay, Seck, Thomas, Woerle, Hans-Juergen

Journal:

Current Medical Research and Opinion

Year:

2015

Language:

english

File:

PDF, 655 KB

english, 2015

74

Diagnostic and Therapeutic Implications of Relationships Between Fasting, 2-Hour Postchallenge Plasma Glucose and Hemoglobin A1c Values

Woerle, Hans J., Pimenta, Walkyria P., Meyer, Christian, Gosmanov, Niyaz R., Szoke, Ervin, Szombathy, Tamas, Mitrakou, Asimina, Gerich, John E.

Journal:

Archives of Internal Medicine

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

75

Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38:394–402

Lewin, Andrew, DeFronzo, Ralph A., Patel, Sanjay, Liu, Dacheng, Kaste, Renee, Woerle, Hans J., Broedl, Uli C.

Journal:

Year:

2015

File:

PDF, 583 KB

2015

76

Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers

Chen, Lin-Zhi, Jungnik, Arvid, Mao, Yanping, Philip, Elsy, Sharp, Dale, Unseld, Anna, Seman, Leo, Woerle, Hans-Jürgen, Macha, Sreeraj

Journal:

Year:

2015

Language:

english

File:

PDF, 679 KB

english, 2015

77

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

Cooper, Mark E., Perkovic, Vlado, McGill, Janet B., Groop, Per-Henrik, Wanner, Christoph, Rosenstock, Julio, Hehnke, Uwe, Woerle, Hans-Juergen, von Eynatten, Maximilian

Journal:

American Journal of Kidney Diseases

Year:

2015

Language:

english

File:

PDF, 463 KB

english, 2015

78

Erratum. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2015;38:384–393

DeFronzo, Ralph A., Lewin, Andrew, Patel, Sanjay, Liu, Dacheng, Kaste, Renee, Woerle, Hans J., Broedl, Uli C.

Journal:

Year:

2015

Language:

english

File:

PDF, 587 KB

english, 2015

79

Encyclopedia of Endocrine Diseases || Glucose Physiology, Normal

Woerle, Hans J.

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

80

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Haering, Hans-Ulrich, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Meinicke, Thomas, Woerle, Hans J., Broedl, Uli C.

Journal:

Diabetes Research and Clinical Practice

Year:

2015

Language:

english

File:

PDF, 471 KB

english, 2015

81

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Kovacs, Christopher S., Seshiah, Veeraswamy, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans-Juergen, Broedl, Uli C.

Journal:

Clinical Therapeutics

Year:

2015

Language:

english

File:

PDF, 689 KB

english, 2015

82

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis

Zinman, Bernard, Ahrén, Bo, Neubacher, Dietmar, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik

Journal:

Canadian Journal of Diabetes

Year:

2015

File:

PDF, 457 KB

2015

83

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Muscelli, Elza, Astiarraga, Brenno, Barsotti, Elisabetta, Mari, Andrea, Schliess, Freimut, Nosek, Leszek, Heise, Tim, Broedl, Uli C., Woerle, Hans-Juergen, Ferrannini, Ele

Journal:

Year:

2016

Language:

english

File:

PDF, 728 KB

english, 2016

84

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers

Macha, Sreeraj, Mattheus, Michaela, Pinnetti, Sabine, Broedl, Uli C., Woerle, Hans J.

Journal:

Clinical Therapeutics

Year:

2015

Language:

english

File:

PDF, 270 KB

english, 2015

85

Different isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans during oral and cutaneous candidosis in vivo

KORTING, HANS C., SCHALLER, MARTIN, JANUSCHKE, ELFRIEDE, SCHACKERT, CAROLIN, WOERLE, BIRGIT

Journal:

Journal of Medical Microbiology

Year:

2001

Language:

english

File:

PDF, 406 KB

english, 2001

86

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Sarashina, Akiko, Koiwai, Kazuki, Seman, Leo J., Yamamura, Norio, Taniguchi, Atsushi, Negishi, Takahiro, Sesoko, Shogo, Woerle, Hans J., Dugi, Klaus A.

Journal:

Drug Metabolism and Pharmacokinetics

Year:

2013

Language:

english

File:

PDF, 946 KB

english, 2013

87

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Roden, Michael, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans J., Broedl, Uli C.

Journal:

Cardiovascular Diabetology

Year:

2015

Language:

english

File:

PDF, 1.67 MB

english, 2015

88

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M., Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.

Journal:

European Heart Journal

Year:

2016

Language:

english

File:

PDF, 465 KB

english, 2016

89

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Neeland, Ian J., McGuire, Darren K., Eliasson, Björn, Ridderstråle, Martin, Zeller, Cordula, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik

Journal:

Diabetes Therapy

Year:

2015

Language:

english

File:

PDF, 848 KB

english, 2015

90

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

Kohler, Sven, Salsali, Afshin, Hantel, Stefan, Kaspers, Stefan, Woerle, Hans J., Kim, Gabriel, Broedl, Uli C.

Journal:

Clinical Therapeutics

Year:

2016

Language:

english

File:

PDF, 441 KB

english, 2016

91

EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK

Fitchett, David H., Inzucchi, Silvio, Lachin, John, Wanner, Christoph, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C., Zinman, Bernard

Journal:

Journal of the American College of Cardiology

Year:

2016

Language:

english

File:

PDF, 364 KB

english, 2016

92

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Rosenstock, Julio, Marx, Nikolaus, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik

Journal:

Cardiovascular Diabetology

Year:

2015

Language:

english

File:

PDF, 618 KB

english, 2015

93

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, Christoph, Inzucchi, Silvio E., Lachin, John M., Fitchett, David, von Eynatten, Maximilian, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Zinman, Bernard

Journal:

New England Journal of Medicine

Year:

2016

Language:

english

File:

PDF, 370 KB

english, 2016

94

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

Cherney, David, Lund, Søren S., Perkins, Bruce A., Groop, Per-Henrik, Cooper, Mark E., Kaspers, Stefan, Pfarr, Egon, Woerle, Hans J., von Eynatten, Maximilian

Journal:

Year:

2016

Language:

english

File:

PDF, 471 KB

english, 2016

95

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials

Yoon, Kun-Ho, Nishimura, Rimei, Lee, Jisoo, Crowe, Susanne, Salsali, Afshin, Hach, Thomas, Woerle, Hans J.

Journal:

Diabetes, Obesity and Metabolism

Year:

2016

Language:

english

File:

PDF, 1.22 MB

english, 2016

96

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

Chen, Yuhong, Ning, Guang, Wang, Changjiang, Gong, Yan, Patel, Sanjay, Zhang, Candice, Izumoto, Toshiyasu, Woerle, Hans-Juergen, Wang, Weiqing

Journal:

Journal of Diabetes Investigation

Year:

2015

Language:

english

File:

PDF, 311 KB

english, 2015

97

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Hadjadj, Samy, Rosenstock, Julio, Meinicke, Thomas, Woerle, Hans J., Broedl, Uli C.

Journal:

Year:

2016

Language:

english

File:

PDF, 1.63 MB

english, 2016

98

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus

Heise, Tim, Jordan, Jens, Wanner, Christoph, Heer, Martina, Macha, Sreeraj, Mattheus, Michaela, Lund, Søren S., Woerle, Hans J., Broedl, Uli C.

Journal:

Clinical Therapeutics

Year:

2016

Language:

english

File:

PDF, 1.11 MB

english, 2016

99

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication

Mancia, Giuseppe, Cannon, Christopher P., Tikkanen, Ilkka, Zeller, Cordula, Ley, Ludwin, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik

Journal:

Year:

2016

Language:

english

File:

PDF, 1.43 MB

english, 2016

100

Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk

Fitchett, David, Inzucchi, Silvio, Lachin, John, Wanner, Christoph, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans Jurgen, Broedl, Uli C., Zinman, Bernard

Journal:

Canadian Journal of Diabetes

Year:

2016

Language:

english

File:

PDF, 71 KB

english, 2016